NeuroPointDX Biological test for autism could lead to earlier identification

A new study from NeuroPointDX of Madison and University of California researchers shows biochemical markers could allow for earlier identification of autism spectrum disorder.

Lead author David Amaral says this discovery could also lead to avenues for therapeutic intervention.

NeuroPointDX is a division of Stemina Biomarker Discovery, also based in Madison, and Amaral is from the MIND Institute at UC Davis. Researchers from the company and university collaborated on a large-scale study to follow up on previous research that had identified new targets for analysis.